Augtyro (repotrectinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:			
important for the review (h any additional documentation that is ation request). Information contained in		
			URGEN		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE:	ZIP CODE:		
PATIENT INSURANCE ID I	NUMBER:				
IF YOU ARE NOT THE PATIENT OR THE PR FOLLOWING LINK: <u>PRIMETHERAPEUTICS.</u>	•	CLOSURE AUTHORIZATION FOR	VI WITH THIS REQUEST WHICH CAN BE FOUND AT THE		
	ATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATION	ON				
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:		
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
		1			
MEDICATION OR MEDIC	AL DISPENSING INFORMATION				
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILL	QUANTITY: S:		
□ NEW THERAPY DURATION OF THERAPY (RENEWAL SPECIFIC DATES):	IF RENEWAL: DA	TE THERAPY INITIATED:		

Prime THERAPEUTICS*

Continued on next page

Augtyro (repotrectinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
□ Non-small cell lung cancer (NSCLC)		ico 10.
□ Locally advanced or metastatic solid	tumors	
I	ICD-10 Code(s):	
3. REQUIRED CLINICAL INFORMATION	I: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A
PRIOR AUTHORIZATION.		
Is patient going to be using drug in a	clinical trial? Yes No	
Does patient have an ECOG score of C	0-1? ☐ Yes ☐ No Please submit documen	itation.
(including primary CNS tumors) that It No Please submit documentation. Has patient progressed following treat Does patient have no satisfactory alto If patient has brain metastases, is patient.	Ily advanced, or metastatic non-small cenarbors an ALK, ROS1, NTRK1, NTRK2, or extended the state of the stat	NTRK3 gene rearrangement? Yes mentation. bmit documentation. ubmit documentation.
physician feels is important to this re	view?	
Please note: Not all drugs/diagnosis a information is received.	re covered on all plans. This request may	be denied unless all required
the Health Plan, insurer, Medical Grou	n provided is true and accurate to the be p or its designees may perform a routine curacy of the information reported on th	audit and request the medical
Prescriber Signature or Electronic I.D.	Verification:	Date:
you are not the intended recipient, you are he	companying this transmission contain confidential reby notified that any disclosure, copying, distributhave received this information in error, please not be as a decuments.	tion, or action taken in reliance on the contents



Augtyro (repotrectinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

